Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)

  • I. V. Litvinenko
  • M. M. Odinak
  • V. I. Mogil’naya
  • A. Yu. Emelin
Article

Abstract

An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (p < 0.05),ADAS-cog (p < 0.05), the clock drawing test (p < 0.05), and the FAB (p < 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (p = 0.0002), anxiety (p = 0.04), sleep disturbance (p = 0.04), and apathy (p = 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (p = 0.007) and improvements in daily activity (p = 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%).

Key Words

Parkinson's disease dementia galantamine 

References

  1. 1.
    Zh. M. Glozman and O. S. Levin, “Mental disorders in extrapyramidal diseases,” in: Extrapyramidal Diseases: Handbook of Diagnosis and Treatment [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), MEDpress-Inform, Moscow (2002), pp. 74–86.Google Scholar
  2. 2.
    V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson's disease and Parkinson's Syndrome [in Russian], MEDpress, Moscow (1999).Google Scholar
  3. 3.
    O. S. Levin and N. A. Amosova, Psychotic Disorders in Parkinson's disease. Scientific-Practical Conference on Parkinson's Disease [in Russian], Moscow (1999), pp. 30–32.Google Scholar
  4. 4.
    O. S. Levin, “Efficacy of Reminyl in dementia with Lewy bodies,” Zh. Nevropatol. Psikhiat., 105, No. 10, 15–21 (2005).Google Scholar
  5. 5.
    D. Aarsland, J. P. Larsen, J. L. Cumming, et al., “Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease,” Arch. Neurol., 56, No. 3, 595–601 (1999).PubMedCrossRefGoogle Scholar
  6. 6.
    D. Aarsland, K. Andersen, J. P. Larsen, et al., “Risk of dementia in Parkinson's Disease: A community-based prospective study,” Neurology, 56, No. 6, 730–736 (2001).PubMedGoogle Scholar
  7. 7.
    D. Aarsland, M. Hutchinson, and J. P. Larsen, “Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia,” Int. J. Geriat. Psychiat., 18, No. 10, 937–941 (2003).CrossRefGoogle Scholar
  8. 8.
    C. Ballard, M. Piggott, and M. Johnson, “Delusions associated with elevated muscarinic binding in dementia with Lewy bodies,” Ann. Neurol., 48, No. 6, 868–876 (2000).PubMedCrossRefGoogle Scholar
  9. 9.
    S. R. Beach and R. Schulz, “Caregiving as a risk factor for mortality: the Caregiver Health Effects Study,” J. Amer. Med. Assoc., 282, No. 23, 2215–2219 (1999).CrossRefGoogle Scholar
  10. 10.
    N. I. Bohnen, D. I. Kaufer, L. S. Ivanco, et al., “Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study,” Arch Neurol., 60: No. 12, 1745–1748 (2003).PubMedCrossRefGoogle Scholar
  11. 11.
    N. I. Bohnen, D. I. Kaufer, R. Hendrickson, et al., “Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia,” J. Neurol., 253, No. 2, 242–247 (2005).PubMedCrossRefGoogle Scholar
  12. 12.
    J. L. Boyd, C. A. Cruikshank, C. W. Kenn, et al., “Cognitive impairment and dementia in Parkinson's disease: a controlled study,” Psychol. Med., 21, No. 3, 911–921 (1991).PubMedGoogle Scholar
  13. 13.
    R. Bullock and A. Cameron, “Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series,” Curr. Med. Res. Opin., 18, No. 5, 258–264 (2002).PubMedCrossRefGoogle Scholar
  14. 14.
    M. J. Catalan-Alonso and J. Del Val, “Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?” Rev. Neurol., 32, No. 11, 1085–1087 (2001).PubMedGoogle Scholar
  15. 15.
    J. L. Cummings, M. Mega, K. Gray, et al., “The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,” Neurology, 44, No. 12, 2308–2314 (1994).PubMedGoogle Scholar
  16. 16.
    C. Da Cunha, M. E. Angelucci, N. S. Canteras, et al., “The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities,” Cell Mol. Neurobiol., 22, No. 3, 227–237 (2002).PubMedCrossRefGoogle Scholar
  17. 17.
    E. Duran Ferreras, J. Chacon, and J. A. Quintana, “The role of olanzapine in Parkinsonian dopaminergic psychosis,” Rev. Neurol., 35, No. 7, 691–696 (2002).PubMedGoogle Scholar
  18. 18.
    K. R. Edwards, L. Hershey, and L. Wray, “Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis,” Dement. Geriat. Cogn. Disord., 17, Supplement 1, 40–48 (2004).CrossRefGoogle Scholar
  19. 19.
    R. L. Ernst and J. W. Hay, “The US economic and social costs of Alzheimer's disease revisited,” Amer. J. Public Health, 84, No. 8, 1261–1264 (1994).PubMedCrossRefGoogle Scholar
  20. 20.
    G. Fabbrini, P. Barbanti, C. Aurilia, et al., “Donepezil in the treatment of hallucinations and delusions in Parkinson's disease,” Neurol. Sci., 23, No. 1, 41–43 (2002).PubMedCrossRefGoogle Scholar
  21. 21.
    G. Fenelon, F. Mahieux, R. Huon, et al., “Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors,” Brain, 123, No. 7, 733–745 (2000).PubMedCrossRefGoogle Scholar
  22. 22.
    J. M. Graham, R. A. Grunewald, and H. J. Sagar, “Hallucinosis,” J. Neurol. Neurosurg. Psychiat., 63, No. 5, 434–440 (1967).Google Scholar
  23. 23.
    D. Grossi, L. Trojano, and M. T. Pellecchia, “Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients,” Int. J. Geriat. Psychiat., 20, No. 7, 668–673 (2005).CrossRefGoogle Scholar
  24. 24.
    K. Ito, A. Nagano-Saito, T. Kato, et al., “Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study,” Brain, 125, No. 6, 1358–1365 (2002).PubMedCrossRefGoogle Scholar
  25. 25.
    I. Leroi, J. Brandt, and S. G. Reich, “Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease,” Int. J. Geriat. Psychiat., 19, No. 1, 1–8 (2004).CrossRefGoogle Scholar
  26. 26.
    T. Mori, M. Ikeda, and R. Fukuhara, “Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB,” Neurology, 66, No. 6, 935–937 (2006).PubMedCrossRefGoogle Scholar
  27. 27.
    K. Okada, N. Suyama, H. Oguro, et al., “Medication-induced hallucination and cerebral blood flow in Parkinson's disease,” J. Neurol., 246, No. 5, 365–368 (1999).PubMedCrossRefGoogle Scholar
  28. 28.
    J. Parkinson, An Essay on the Shaking Palsy, Sherwood, Neely and Jones, London (1817), p. 66.Google Scholar
  29. 29.
    E. Perry, D. Irving, J. M. Kerwin, et al., “Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease,” Alzheimer. Dis. Assoc. Disord., 7, No. 2, 69–79 (1993).PubMedCrossRefGoogle Scholar
  30. 30.
    I. H. Richard, A. W. Justus, N. H. Greig, et al., “Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine,” Clin. Neuropharmacol., 25, No. 6, 296–299 (2002).PubMedCrossRefGoogle Scholar
  31. 31.
    M. Rosler, “The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia,” Int. J. Clin. Pract., 127, Supplement 1, 20–36 (2002).Google Scholar
  32. 32.
    A. J. Saykin, H. A. Wishart, and L. A. Rabin, “Cholinergic enhancement of frontal lobe activity in mild cognitive impairment,” Brain, 127, No. 7, 1574–1583 (2004).PubMedCrossRefGoogle Scholar
  33. 33.
    W. S. Shaw, T. L. Patterson, and S. J. Semple, “Longitudinal analysis of multiple indicators of health decline among spousal caregivers,” Ann. Behav. Med., 19, No. 2, 101–109 (1997).PubMedCrossRefGoogle Scholar
  34. 34.
    C. Summerfield, B. Gomez-Anson, E. Tolosa, et al., “Dementia in Parkinson's disease: a proton magnetic resonance spectroscopy study,” Arch., Neurol., 59, No. 9, 1415–1420 (2002).CrossRefGoogle Scholar
  35. 35.
    T. Sunderland, J. L. Hill, A. M. Mellow, et al., “Clock drawing in Alzheimer's disease: a novel measure of dementia severity,” J. Amer. Geriat. Soc., 37, No. 5, 725–729 (1989).PubMedGoogle Scholar
  36. 36.
    P. N. Tariot, P. R. Solomon, J. C. Morris, et al., “A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group,” Neurol., 54, No. 12, 2269–2276 (2000).Google Scholar
  37. 37.
    E. Y. Uc, M. Rizzo, and S. W. Anderson, “Visual dysfunction in Parkinson disease without dementia,” Neurology, 65, No. 12, 1907–1913 (2005).PubMedCrossRefGoogle Scholar
  38. 38.
    C. H. Van Dyck, P. Tariot, M. Farlow, et al., “Memantine/donepezil dual-therapy is superior to placebo/donepezil for treatment of moderate to severe Alzheimer's disease,” in: Abstracts of the 6th International Conference on Alzheimer's Disease and Parkinson's Disease, Seville, Spain (2003), p. 491.Google Scholar
  39. 39.
    R. J. Van Marum and P. A. Jansen, “Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia,” Ned. Tijdschr. Geneeskd., 149, No. 4, 165–167 (2005).PubMedGoogle Scholar
  40. 40.
    S. P. Woods and A. I. Troster, “Prodromal fontal/executive dysfunction predicts incident dementia in Parkinson's disease,” J. Int. Neuropsychol. Soc., 9, No. 1, 17–24 (2003).PubMedCrossRefGoogle Scholar
  41. 41.
    C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chaul, “Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases,” Arch. Neurol., 60, No. 3, 337–341 (2003).PubMedCrossRefGoogle Scholar
  42. 42.
    I. Zhang, F. Zhou, and J. A. Dani, “Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release,” Mol. Pharmacol., 66, No. 3, 538–544 (2004).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2008

Authors and Affiliations

  • I. V. Litvinenko
    • 1
  • M. M. Odinak
    • 1
  • V. I. Mogil’naya
    • 1
  • A. Yu. Emelin
    • 1
  1. 1.Department of Nervous DiseasesMilitary Medical AcademySt. PetersburgRussia

Personalised recommendations